Dr. Reddy’s issues 375 ESOP shares to staff

Dr. Reddy’s Laboratories issues 375 equity shares on ESOP exercise, marginally increasing its total issued share capital.

Rhea-AI Filing Summary

DR REDDYS LABORATORIES LTD (RDY) reports the allotment of 375 equity shares of face value Re.1 each on September 10, 2026, to employees exercising stock options under the Dr. Reddy’s Employees ADR Stock Option Scheme, 2007. These fully paid shares rank pari passu with existing equity shares.

Total issued shares after this allotment are 834,681,285, with total issued share capital of Rs. 834,681,285. The paid-up capital reflects 834,680,285 equity shares, with a difference of 1,000 shares due to forfeited shares from September 1988.

Filing Explained

Employees exercised options at Re.1 per share with no premium, and Dr. Reddy’s completed the allotment of 375 fully paid equity shares on September 10, 2026; this adds issued shares rather than merely reserving or registering them.

Key Figures

Number of shares issued on ESOP exercise: 375 equity shares Par value per share: Re.1 per share Exercise price per share: Re.1 per share +4 more

7 metrics

Number of shares issued on ESOP exercise 375 equity shares Allotted on September 10, 2026 under Employees ADR Stock Option Scheme, 2007

Par value per share Re.1 per share Face value of newly allotted equity shares

Exercise price per share Re.1 per share Price paid by employees on stock option exercise

Total issued shares after allotment 834,681,285 shares Total issued equity shares after ESOP allotment

Total issued share capital after allotment Rs. 834,681,285 Share capital corresponding to total issued shares

Total paid-up share capital Rs. 834,680,285 834,680,285 equity shares of Re.1 each after this issue

Forfeited shares causing capital difference 1,000 shares Forfeited in September 1988 for non-payment of allotment money

Key Terms

ESOPs, SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, ADR, pari passu, +1 more

5 terms

ESOPs financial

"Allotment of Equity Shares on exercise of Stock Options under ESOPs"

SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 regulatory

"details as required under Regulation 10(c) of the SEBI (Share Based"

ADR financial

"Dr. Reddy’s Employees ADR Stock Options Scheme, 2007"

An American Depositary Receipt (ADR) is a financial certificate that lets investors buy shares of a foreign company through U.S. stock markets, similar to buying a local wrapper that represents the underlying foreign shares. ADRs matter because they make investing in overseas companies easier and more liquid by trading in U.S. dollars and under U.S. market rules, while still carrying currency, regulatory, and country-specific risks that can affect share value.

pari passu financial

"Yes, the shares rank pari passu with the existing shares"

An instruction that different claims, securities, or creditors are treated equally and share rights or payments on the same priority level. For investors, it means their position will be paid or have voting power alongside others in the same class rather than being favored or subordinated—think of several people standing in one bus line who all get on together rather than some cutting ahead. That parity affects expected recovery in reorganizations, dividend order, and relative risk.

forfeited shares financial

"difference of 1,000 due to forfeited shares of Re. 1/- each in September 1988"

FAQ

What did DR REDDYS LABORATORIES LTD (RDY) announce in this Form 6-K?

DR REDDYS LABORATORIES LTD announced the allotment of 375 equity shares of Re.1 each on September 10, 2026, to employees who exercised stock options under the Dr. Reddy’s Employees ADR Stock Option Scheme, 2007.

Under which ESOP scheme were the new RDY shares allotted?

The 375 equity shares were allotted under the Dr. Reddy’s Employees ADR Stock Option Scheme, 2007, an employee stock option plan that complies with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

What is the exercise price and par value of the newly allotted RDY shares?

Each newly allotted share has a par value of Re.1 and an exercise price of Re.1 per share, with no premium. All 375 shares are fully paid up as a result of the employees’ stock option exercise.

How many DR REDDYS (RDY) shares are issued after this ESOP allotment?

After the allotment of 375 shares, total issued shares are 834,681,285 equity shares, and total issued share capital is Rs. 834,681,285, as stated in the disclosure under SEBI’s share-based benefit regulations.

What is the total paid-up share capital of DR REDDYS (RDY) after this issue?

Total paid-up capital after this issue is 834,680,285 equity shares of Re.1 each, aggregating to Rs. 834,680,285. The company explains a difference of 1,000 shares due to forfeited shares from September 1988 for non-payment of allotment money.

Are the newly issued RDY shares identical to existing shares?

Yes. The company states that the newly issued equity shares rank pari passu with the existing shares, meaning they are identical in all respects to the current equity shares listed on the BSE, NSE and as ADRs on the NYSE and NSE IFSC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 11:18 AM Accepted by SEC EDGAR 09/10/2026 - 11:18 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

September, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x                             Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                             No   x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated September 10, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED  (Registrant)
Date: September 10, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

Exhibit 99.1

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com

Sep 10, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Ltd. (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Sub: Allotment of Equity Shares on exercise of Stock Options under ESOPs

This is to inform you that the Company has allotted 375 equity shares of Re.1/- each of the Company, fully paid up, on September 10, 2026, to eligible employees pursuant to exercise of their Stock Options under Dr. Reddy’s Employees ADR Stock Options Scheme, 2007.

Further, please find enclosed the details as required under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

Encl: as above

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com

Details under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021

1	Company name and address of Registered Office: Dr. Reddy's Laboratories Limited 8-2-337, Road No.3, Banjara Hills, Hyderabad – 500034
2	Name of the Stock Exchanges on which the company’s shares are listed: BSE Limited National Stock Exchange of India Limited New York Stock Exchange Inc. (ADRs) NSE IFSC Limited (ADRs)
3	Filing date of the statement referred in Regulation 10(b) of the SEBI (Share Based Employee Benefits) Regulations, 2021 with Stock Exchange: The Schemes were institutionalised under the erstwhile the SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 and appropriate details under Schedule V were filed. The Schemes comply with provisions of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
4	Filing Number, if any: NA
5	Title of the Scheme pursuant to which shares are issued, if any: Dr. Reddy’s Employees ADR Stock Option Scheme, 2007
6	Kind of security to be listed: Equity Shares
7	Par value of the shares: Re. 1/-
8	Date of issue of shares: September 10, 2026 (Date of allotment on exercise)
9	Number of shares issued: 375 equity shares
10	Share Certificate No., if applicable: NA
11	Distinctive number of the share, if applicable: 834679911 to 834680285
12	ISIN Number of the shares if issued in Demat: INE089A01031
13	Exercise price per share: Re.1/- per share
14	Premium per share: Nil
15	Total Issued shares after this issue: 83,46,81,285 (*)
16	Total Issued share capital after this issue: Rs. 83,46,81,285 /-
17	Details of any lock-in on the shares: NA
18	Date of expiry of lock-in: NA
19	Whether shares identical in all respects to existing shares if not, when will they become identical? Yes, the shares rank pari passu with the existing shares
20	Details of listing fees, if payable: NA

(*) Total paid up capital after this issue: 83,46,80,285 equity shares of Re.1 each, aggregating to Rs. 83,46,80,285/- (difference of 1,000 due to forfeited shares of Re. 1/- each in September 1988 on account of non-payment of allotment money.)

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 73.5 KB